Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity - eBioMedicine

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells. - Abstract - Europe PMC

Frontiers Therapeutic strategies for gastric cancer targeting immune cells: Future directions

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC

Biomedicines, Free Full-Text

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. - Abstract - Europe PMC

AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. - Abstract - Europe PMC

Frontiers Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy

AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice - eBioMedicine

IFN-γ independent markers of Mycobacterium tuberculosis exposure among male South African gold miners - eBioMedicine

PDF) Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. - Abstract - Europe PMC